What is Wedbush’s Estimate for VRDN FY2028 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities researchers at Wedbush cut their FY2028 earnings estimates for Viridian Therapeutics in a report issued on Wednesday, August 6th. Wedbush analyst L. Chico now forecasts that the company will earn $5.11 per share for the year, down from their previous estimate of $5.43. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.00). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 72.85% and a negative net margin of 112,806.88%. Viridian Therapeutics’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.81) earnings per share.

A number of other research firms also recently weighed in on VRDN. Oppenheimer increased their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday. Wells Fargo & Company decreased their price objective on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Thursday. Royal Bank Of Canada decreased their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating for the company in a report on Thursday. JMP Securities decreased their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, Needham & Company LLC decreased their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $16.41 on Friday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.28 and a beta of 0.42. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $27.20. The stock has a fifty day simple moving average of $15.95 and a 200 day simple moving average of $15.19. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Viridian Therapeutics by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company’s stock worth $88,087,000 after purchasing an additional 174,952 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Viridian Therapeutics by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company’s stock worth $31,809,000 after purchasing an additional 165,669 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in shares of Viridian Therapeutics during the 4th quarter worth about $493,000. FMR LLC boosted its position in shares of Viridian Therapeutics by 6.2% during the 4th quarter. FMR LLC now owns 11,881,912 shares of the company’s stock worth $227,776,000 after purchasing an additional 698,434 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of Viridian Therapeutics by 59.5% during the 4th quarter. Invesco Ltd. now owns 33,099 shares of the company’s stock worth $635,000 after purchasing an additional 12,350 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.